Русский
Efficiency of immunomodulatotors for complex therapy of chronic recurrent cystitis in women
DOI: https://dx.doi.org/10.18565/urology.2019.2.9-14
A.V. Kuz’menko, V.V. Kuz’menko, T.A. Gyaurgiev
Department of Urology (Head – MD, ass. prof. A.V. Kuz’menko) of FGBOU VO «Voronezh State Medical University named after N.N. Burdenko, Voronezh, Russia
Introduction. Currently, chronic recurrent cystitis is one of the most important problems in urology. Considering the role of immune status disorders in the pathogenesis of inflammatory diseases, the use of immunocorrective drugs as part of the complex therapy is of particular relevance.
Aim: to study the efficiency of therapy for chronic recurrent bacterial cystitis in combination with immunomodulators (Galavit).
Materials and methods. A total of 60 women with acute stage of chronic recurrent bacterial cystitis were examined. The patients were randomized into 2 groups of 30 patients. In the control group, standard antibiotic therapy was administered. In the treatment group, patients received Galavit in combination with standard therapy. All patients were followed-up on the 1st, 5th and 10th day. Voiding diaries, chronobiological status and pain severity using a 5-point scale were evaluated. In addition, complete blood count, urinalysis, urine culture and enzyme immunoassay for determination of serum level of interleukin (IL) 1, IL-6, tumor necrosis factor α (TNF-α) were analyzed. A number of recurrences after 3 months of therapy was assessed.
Results. Complex therapy in combination with Galavit in women with acute stage of chronic bacterial cystitis allows to decrease in desynchronosis by 20%, reduce pain by 2.5 times, frequency of urination by 1.7 times, the number of urgent voids and night urination by 2.4 and 5 times, respectively, by the 5th day of therapy. In the group of patients receiving immunomodulators a significantly more pronounced decrease in the level of IL-1, IL-6, TNF–α and CRP was noted. During 3 months of follow-up, there were 2 recurrences in the control group and no recurrences in treatment group (10%).
Conclusion. The use of Galavit in the treatment of women with chronic recurrent bacterial cystitis has pathogenetic basis. A clear advantage of the drug is more rapid relief of symptoms, normalization of laboratory parameters, recovery of chronorhythms and the achievement of clinical remission.
Aim: to study the efficiency of therapy for chronic recurrent bacterial cystitis in combination with immunomodulators (Galavit).
Materials and methods. A total of 60 women with acute stage of chronic recurrent bacterial cystitis were examined. The patients were randomized into 2 groups of 30 patients. In the control group, standard antibiotic therapy was administered. In the treatment group, patients received Galavit in combination with standard therapy. All patients were followed-up on the 1st, 5th and 10th day. Voiding diaries, chronobiological status and pain severity using a 5-point scale were evaluated. In addition, complete blood count, urinalysis, urine culture and enzyme immunoassay for determination of serum level of interleukin (IL) 1, IL-6, tumor necrosis factor α (TNF-α) were analyzed. A number of recurrences after 3 months of therapy was assessed.
Results. Complex therapy in combination with Galavit in women with acute stage of chronic bacterial cystitis allows to decrease in desynchronosis by 20%, reduce pain by 2.5 times, frequency of urination by 1.7 times, the number of urgent voids and night urination by 2.4 and 5 times, respectively, by the 5th day of therapy. In the group of patients receiving immunomodulators a significantly more pronounced decrease in the level of IL-1, IL-6, TNF–α and CRP was noted. During 3 months of follow-up, there were 2 recurrences in the control group and no recurrences in treatment group (10%).
Conclusion. The use of Galavit in the treatment of women with chronic recurrent bacterial cystitis has pathogenetic basis. A clear advantage of the drug is more rapid relief of symptoms, normalization of laboratory parameters, recovery of chronorhythms and the achievement of clinical remission.
About the Autors
Corresponding author: A.V. Kuz’menko– MD, associate professor, Head of Department of Urology of FGBOU VO «Voronezh State Medical University named after N.N. Burdenko», Voronezh, Russia; e-mail: Kuzmenkoav09@yandex.ru
Similar Articles
